Combined oral and topical mesalazine treatment for extensive ulcerative colitis

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 5, 2006, Pages 290-293

  Moss, Alan C ^a   Cheifetz, Adam S ^b   Peppercorn, Mark A ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Mesalazine; Oral therapy; Steroids; Topical therapy; Ulcerative colitis

Indexed keywords

GRANULOCYTE ANTIBODY; MESALAZINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; FECES CULTURE; FEMALE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; RECTUM BIOPSY; REMISSION; SACCHAROMYCES CEREVISIAE; SIGMOIDOSCOPY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; ENEMA; FEMALE; HUMANS; MESALAMINE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 33646389862     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0475     Document Type: Article

References (26)

1. Farrell RJ and Peppercorn MA (2002) Ulcerative colitis. Lancet 359: 331-340
2. Alstead EM and Nelson-Piercy C (2003) Inflammatory bowel disease in pregnancy. Gut 52: 159-161
3. Elbaz G et al. (2005) Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 90: 193-197
4. Travis SP (2004) Review article: The management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 20 (Suppl 4): 88-92
5. Olsen KO et al. (1999) Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 86: 493-495
6. Ferrero S and Ragni N (2004) Inflammatory bowel disease: Management issues during pregnancy. Arch Gynecol Obstet 270: 79-85
7. Hanauer S et al. (1993) Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88: 1188-1197
8. Miglioli M et al. (1990) Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: A dose ranging study. Eur J Gastroenterol Hepatol 2: 229-234
9. Riley SA et al. (1988) Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29: 669-674
10. Schroeder KW et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629
11. Sninsky CA et al. (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115: 350-355
12. Hanauer SB et al. (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II Trial. Am J Gastroenterol 100: 2478-2485
13. Gisbert JP et al. (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: A systematic review. Dig Dis Sci 47: 471-488
14. Sutherland L and MacDonald JK (2003) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews, Issue 3, Art. No CD000543
15. Kruis W et al. (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1: 36-43
16. Campieri M et al. (1990) Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 25: 663-668
17. Campieri M et al. (1991) Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32: 929-931
18. Hanauer SB et al. (1998) Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis 4: 79-83
19. Cohen RD et al. (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95: 1263-1276
20. Frieri G et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13: 1413-1417
21. Safdi M et al. (1997) A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92: 1867-1871
22. D'Albasio G et al. (1997) Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double blind study. Am J Gastroenterol 92: 1143-1147
23. Piodi LP et al. (2004) Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 39: 154-157
24. Paoluzi P et al. (2002) Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: One-year randomised multicenter trial. Dig Liver Dis 34: 787-793
25. Vecchi M et al. (2001) Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 15: 251-256
26. Marteau P et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study. Gut 54: 960-965